Serological and molecular analysis of parvovirus B19 infection in Mayan women with systemic lupus erythematosus in Mexico.
Article Sidebar
Main Article Content
Background:
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that mainly affects women, characterized by the production of autoantibodies. Its causal agent is unknown, but the combination of environmental, hormonal and genetic factors may favor the development of the disease. Parvovirus B19 has been associated with the development of SLE, since it induces the production of anti-single stranded DNA antibodies. It is unknown whether PV-B19 infection is an environmental factor that trigger or reactivate SLE in the Mexican Mayan population.
Aim:
A preliminary serological and molecular study of PV-B19 infection in Mayan women with established SLE was done.
Methods:
IgG and IgM anti PV-B19 were evaluated in 66 SLE patients and 66 control subjects, all women of Mayan origin. Viral DNA and viral load were analyzed by qPCR.
Results:
Insignificant levels of IgM were observed in 14.3% (4/28) of the patients and 11.4% (4/35) of control subjects. IgG was detected in 82.1% (23/28) of the patients and 82.9% (29/35) of control subjects, but were significantly higher in patients. Viral DNA was found in 86.0% (57/66) of the patients and 81.0% (54/66) of control subjects. Viral load, quantified in 28/66 patients and 31/66 controls which were positive for IgM and IgG, was significantly higher in controls.
Conclusion:
The high prevalence of PV-B19 in Yucatan, and the presence of IgM, IgG, and viral load in Mayan women with established SLE suggest that PV-B19 infection could be an environmental factor to trigger or reactivate SLE.
Vyse TJ, Kotzin BL. Genetic susceptibility to systemic Lupus Erythematosus. Annu Rev Immunol. 1998; 16: 261-292.
Lispky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001; 2:764-766.
Crispín JC, Nick S, Liossis C, Kis-Toth K, Lieberman, LA, Kyttaris Y, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010; 16(2):47-57.
Danchencho N, Satia JA, Anthony SM. Lupus around the world. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15:308-318.
Jakes R, Bae S, Louthrenoo W, Mok C, Navarra S, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012; 64:159-68.
Yang N, Li H, Criswell LA, Gregersen PK, Alarcon-Riquelme ME, Kittles R, et al. Examination of ancestry and ethnic affiliation using highly informative diallelic DNA markers: application to diverse and admixed populations and implications for clinical epidemiology and forensic medicine. Hum Genet, 2005; 118:382-392.
Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A, et al. Analysis of genomic diversity in Mexican Mestizo population to develop genomic medicine in Mexico. Proc Natl Acad Sci U S A. 2009; 26:106(21):8611-6.
Peláez-Ballestas I, Sanin L, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al. Epidemiology of the rheumatic diseases in Mexico. A Study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86:3-8.
Álvarez-Nemegyei J, Peláez-Ballestas I, Sanin L, Cardel M, Ramirez-Angulo A, Goycochea-Robles M. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-Based community survey. J Rheumatol Suppl. 2011; 86:21-5.
Esposito S, Bosis S, Semino S, Rigante D. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 2014; 33(9): 1467-1475.
Cooper G, Gilbert K, Greidinger E, James J, Pfau J, Reinlib L, Richardson B, Rose N. Recent advances and opportunities in research on Lupus: environmental influences and mechanisms of disease. Environ Health Perspect. 2008; 116 (6): 695-702.
Rigante D, Benedetta M, Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoinmun Rev. 2014; 13: 96-102.
Cossart YE, Cant E, Field AM, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975; 11(1): 72-73.
Ozawa K, Young N. Characterization of capsid and non-capsid proteins of B19 parvovirus propagated in human erythroid bone marrow culture. J Virol. 1987; 61: 2627-2630.
Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002; 76: 9124-9134.
Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythovirus variant, A6. Virology. 2002; 301:374-380.
Liefeldt L, Plentz A, Klempa B, Kershaw O, Endres AS, Raab U. et al. Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J Med Virology. 2005; 75: 161-169.
Sanabani S, Neto WK, Pereira J, Sabino EC. Sequence variability of human erythrovirus present in bone marow of Brazilian patients with various parvovirus B19-related hematological symptoms. J. Clin Microbiol. 2006; 44: 604-606.
Cohen B, Gandhi J, Clewley J. Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. J Gen Virol. 2006; 36: 152-155.
Corcoran C, Hardie D, Yeats J, Smuts H. Genetic variants of human parvovirus B19 in South Africa: cocirculation of three genotypes and identification of a novel subtype of genotype 1. J Clin Microbiol. 2010; 48: 137-142.
Hübschen JM, Mihneva Z, Mentis AF, Schneider F, Aboudy Y, Grossman Z, et al. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol. 2009; 47: 3735-3738.
Toan NL, Duechting A, Kremsner PG, Song le H, Ebinger M, Aberle S, et al. Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol. 2006; 87: 2941-2949.
Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis.1986; 154: 383-93.
Wu C-g, Mason B, Jong J, Erdman D, McKernan L, Oakley M, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2005; 45: 1003-10.
Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang. 1997; 72:1-10.
Brown KE, Anderson SM, Youmg N. Erythrocyte P antigen cellular receptor of B19 parvovirus. Science. 1993; 262:114-17.
Broliden K, Tolfvenstam T. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006; 260: 285-304.
Aslanidis S, Pyrpasopoulou A, Kontotasios K, Doumas S, Zamboulis C. Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway? Eur J Intern Med. 2008; 19: 314-318.
Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and Molecular Evidence for the Association of SLE with parvovirus B19. Lupus. 2010; 19: 783-792.
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988; 25: 151-3.
Kelly HA, Siebert D, Hammond R, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000; 124: 449-57.
Nabae K, Satoh H, et al . Estimating the risk of parvovirus B19 infection in blood donorss and pregnant women in Japan. Plos One. 2014; 9: 1-8.
Enders M, Weidner A, Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect. 2007; 135: 563-569.
Tapia H, Barriga G, Castillo N. La infección por Parvovirus B19 en México. Rev Mex Patol Clín. 1995; 42(4): 160-163.
Vera L, Gonzalez P, Valadez N, Kancab R, Pavia N, Moguel W, Alonso L, Quintal I, Paredes E. Seroprevalence of parvovirus B19 and associated factors in pregnant women of rural communities of Yucatan, Mexico. Rev Clín Univ Costa Rica. Congreso Mesoamericano de Ciencias Médicas. 2013; 3: 1-2.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35: 630-640.
Schwarz TF, Jäger G. A recombinant immunoblot and Elisa for detection of acute Parvovirus B 19 infection. Zbl Bakt. 1994; 280: 526-533.
Sambrook J, Fritch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Plainview, N.Y.: Cold Spring Harbor Laboratory Press; 1989.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al . The MIQE guidelines minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55: 611-622.
Bonvicini F, Manaresi E, Bua G, Venturoli S, Gallinela G. Keeping pace with Parvovirus B19 genetic variability: a multiplex genotype-specific quantitative PCR assay. J Clin Microbiol. 2013; 51(11): 3753-3759.
Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013; 3(3):71-85.
Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res. 1988; 16(22): 10881-90.
Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol. 2000; 7(1-2):203-14.
Morgulis A, Coulouris G, Raytselis Y, Madden TL, Agarwala R, Schäffer AA. Database indexing for production MegaBLAST searches. Bioinformatics. 2008; 24:1757-1764.
Modrov S, Dorsch S. Antibody response in parvovirus B19 infected patients. Pathol Biol. 2002; 50: 326-31.
Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986; 24: 522-526.
Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol. 1991; 35: 110-115.
Cope AP, Jones A, Brozovic M, Shafi MS, Maini RN. Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis. 1992; 51: 803-804.
Chassagne PL, Mejjad O, Gourmelen O, Moore N, Le Loet X, Deshayes P. Exacerbation of systemic lupus erythematosus during human parvovirus B19 infection. Br J Rheumatol. 1993; 32: 158-159.
Ramos-Casals M, Cuadrado MK, Alba P. Sanna G, Brito-Zerron P. Bertolaccini L, et al . Acute viral infections in patients with systemic lupus erythematosus. Description of 23 cases and review of the literature. Medicine (Baltimore). 2008; 87: 311-8.
Pugliese A, Beltramo T, Torre D, Roccatello D. Parvovirus B19 and immune disordes. Cell Biochem Funct. 2007; 25: 639-641.
Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients; susceptibility factors and preventive strategies. Lupus. 2013; 22: 1286-1294.
Esposito S, Bosis S, Semino M, Rigante D. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 2014; 33: 1467-1475.
Kumar S, Gupta RM, Sen S, Sarkar RS, Philip J, Kotwal A, Sumathi SH. Seroprevalence of human parvovirus B19 in healthy blood donors. Med J Armed Forces India. 2013; 69: 268-272.
Antezana A, Kyster I, et al. A case of encephalopathy in an immunocompetent adult with persistent parvovirus B19 viremia. Open Neurol J. 2015; 9: 1-9..
Downloads
Accepted 2017-08-30
Published 2017-09-20
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use